The Scripps Research Institute Announces New Research and License Agreement with Janssen Pharmaceuticals, Inc.
“We’re delighted to partner with Janssen in this work that could have a significant impact on human health,” said
The new agreement builds on research on the influenza virus conducted jointly by TSRI and Janssen’s Crucell Vaccine Institute. Previous collaborations have resulted in several high-impact publications, most recently in
Seasonal flu typically causes more than 200,000 hospitalizations and 36,000 deaths every year in
The new strategic collaboration with Janssen follows TSRI’s announcement of a five-year agreement with Bristol-Myers Squibb last June; that agreement covered the development of chemistry methodologies and related work.
Forrest notes that promising future areas for corporate partnerships at TSRI include Oncology, Neurodegeneration and Immunology.